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Platelets play a central role in both the short- and long-term manifestations of atherothrom-
bosis. In acute coronary syndrome (ACS), there is a steep rise in cardiovascular events early,
followed by an incremental rise in cardiovascular events over the long term. This long-term
event rate is related to persistent platelet activation and thrombin generation. There is
therefore a need to optimize both short- and long-term oral antiplatelet and antithrombotic
strategies. The benefits of aspirin therapy, when administered early and continued over the
long term, were demonstrated in several early randomized trials. The Antithrombotic
Trialists’ Collaboration found a 46% reduction in vascular events with antiplatelet therapy
(mostly aspirin). However, despite treatment with aspirin and proven therapies, recurrent
events remain high. The adenosine diphosphate receptor antagonists, ticlopidine and
clopidogrel, inhibit the early steps of platelet activation, degranulation, and release of
prothrombotic and inflammatory mediators, while also preventing activation of the glyco-
protein IIb/IIIa receptor. The Clopidogrel in Unstable angina to prevent Recurrent Events
(CURE) trial demonstrated the benefits of aspirin plus clopidogrel in reducing major
cardiovascular events (cardiovascular death, myocardial infarction [MI], and stroke reduced
by 20%, p  0.00009) in a broad range of patients with ACS when administered early and
continued over the long term. The benefits emerge very rapidly after a 300 mg loading dose.
For the large number of patients undergoing percutaneous coronary intervention in the
CURE trial, there was a substantial risk reduction with clopidogrel pretreatment followed by
long-term therapy (p  0.002). This benefit was present, regardless of whether intervention
was performed early or late. The significant benefits of aspirin and clopidogrel persist for the
combined efficacy-safety end point of cardiovascular death, MI, stroke, or life-threatening
bleeding when clopidogrel is started early, combined with aspirin and other standard
therapies, and continued for up to one year. (J Am Coll Cardiol 2003;41:79S–88S) © 2003
by the American College of Cardiology Foundation
The role of platelets in atherothrombosis. Platelets play a
central role in the pathophysiology of atherothrombosis.
There are three essential steps involved in the formation of
a platelet-rich thrombus after plaque disruption: platelet
adhesion, platelet activation, and platelet aggregation.
Platelet adhesion occurs shortly after an atherosclerotic
plaque has ruptured, eroded, or become disrupted, and it is
mediated mainly via the platelet glycoprotein (GP) IIb
receptor through its interaction with von Willebrand factor.
Platelet activation involves several interrelated processes
(Fig. 1). First, the three-dimensional shape of the platelet
changes from a smooth discoid appearance into a spiculated
form, greatly increasing the surface area of the platelet
membrane where thrombin is generated. Next, degranula-
tion or secretion of alpha and dense granules takes place
within the platelet. This releases the prothrombotic, inflam-
matory, and chemo-attractant mediators that propagate,
amplify, and sustain the atherothrombotic process. Finally,
platelet activation leads to a conformational change in the
GP IIb/IIIa receptor, converting the receptor into a form
that can bind fibrinogen and link with other platelets
(platelet aggregation). This final step occurs relatively late,
after atherothrombosis is already far advanced.
Rationale for long-term therapy. In patients with acute
coronary syndrome (ACS), there is an ongoing thrombotic
stimulus, characterized by persistent platelet activation and
thrombin generation. Over months or years, this process
plays an important role in the genesis of recurrent ischemic
events. Clinically, the results are seen during long-term
follow-up of patients with unstable angina or non–ST-
segment elevation myocardial infarction (NSTEMI), in
whom there is a high rate of recurrent major ischemic
events. For example, in a six-month follow-up after hospital
discharge of over 8,000 patients with unstable angina or
NSTEMI, about 6% of patients developed cardiovascular
death, myocardial infarction (MI), or stroke (1). A two-year
follow-up found an event rate of approximately 6% to 8%
per year (2). Such results have focused attention on the need
to optimize long-term oral antiplatelet and antithrombotic
strategies in patients with ACS, to accompany standard
approaches such as statin therapy, angiotensin-converting
enzyme (ACE) inhibition, and smoking cessation.
The clinical observations have been supported by an
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increasing accumulation of angioscopic, angiographic, and
biochemical data. First, angioscopic studies have shown
that, despite the use of short-term antithrombotic therapies,
coronary thrombi are still present for up to 30 days after an
acute ischemic event. Therefore, a longer duration of
antithrombotic therapy may be required to reduce events,
perhaps allowing passivation of the culprit lesion (3). Sec-
ond, there is now good evidence to suggest that patients
with ACS have, in addition to the culprit lesion, multiple
complex coronary plaques that are associated with adverse
clinical outcomes. For example, in a careful angiographic
study, patients who were found to have multiple complex
coronary plaques had an 11-fold increase in recurrent ACS
and a six- to seven-fold increase in multiple adverse cardiac
events (4). This suggests that plaque instability may be
caused by a widespread process affecting the entire coronary
tree (e.g., an inflammatory process) rather than by a single
culprit lesion. Third, angioscopic studies have indicated a
high rate of coronary thrombi in the coronary artery not
supplying the culprit vessel (5). Fourth, biochemical studies
have indicated persistent platelet hyperactivity and elevation
of markers of the coagulation system, suggesting that the
environment for re-thrombosis is still present many months
after the initial event (6–8). Fifth, as indicated earlier,
long-term studies have demonstrated a significant increase
in major cardiovascular events, despite modern day treat-
ments (1,9). In addition, once most short-term antithrom-
botic therapies are terminated, no added benefit is demon-
strated, and clinical events accumulate in both treatment
and control groups. This suggests that longer-term anti-
thrombotic therapy is needed (10,11). Such intriguing
observations, when coupled with emerging data on the
importance of inflammation and coagulation in athero-
thrombosis, support the concept that a generalized, persis-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACS  acute coronary syndrome(s)
ADP  adenosine diphosphate
CABG  coronary artery bypass graft
GP  glycoprotein
MI  myocardial infarction
NSTE  non–ST-segment elevation
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary angioplasty
RR  risk reduction
Figure 1. Platelet activation is an important early step in the pathophysiology of atherothrombosis. Platelet activation involves: 1) a shape change in which
the platelet membrane surface area is greatly increased; 2) the secretion of pro-inflammatory, prothrombotic, adhesive, and chemotactic mediators (release
reaction), that propagate, amplify, and sustain the atherothrombotic process; and 3) the activation of the glycoprotein (GP) IIb/IIIa receptor from its
inactive form. Multiple agonists including thromboxane A2 (TXA2), adenosine diphosphate (ADP), thrombin, serotonin, epinephrine, and collagen, can
activate the platelet and thus contribute toward establishing the environmental conditions necessary for atherothrombosis to occur. Aspirin inhibits the
production of thromboxane A2 by its effect on the enzyme cyclooxygenase (COX) 1. The ADP receptor antagonists clopidogrel and ticlopidine prevent the
binding of ADP to its receptor. The effect of combining aspirin and clopidogrel is synergistic in preventing platelet aggregation. Antithrombins such as
unfractionated or low-molecular-weight heparin, hirudin, or bivalirudin are important in interfering with both thrombin-induced platelet activation and
coagulation. The GP IIb/IIIa receptor antagonists act at a later step in the process by preventing fibrinogen mediated cross-linking of platelets, which have
already become activated. ATP  adenosine triphosphate; PAI  plasminogen activator inhibitor; PDGF  platelet-derived growth factor; vWF  von
Willebrand factor.
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tent process is an important feature of future plaque disrup-
tions and ischemic events. Acute coronary events commonly
result from thrombosis triggered by plaque disruption.
Therefore, functional attributes of the plaque, rather than
the degree of stenosis alone, may determine the propensity
of plaques to rupture, to produce a superimposed thrombus,
and ultimately to provoke ischemic events (12). Thus,
long-term antithrombotic therapy with additional risk-
factor modification has the potential to make a major impact
in the prevention of recurrent events. This article focuses
primarily on the role of oral antithrombotic therapies in
ACS and percutaneous coronary intervention (PCI), in-
cluding aspirin, and the adenosine diphosphate (ADP)
receptor antagonists, clopidogrel and ticlopidine, alone and
in combination.
Aspirin. Aspirin inhibits platelet cyclooxygenase by irre-
versible acetylation, thereby preventing the formation of
thromboxane A2. In addition to the anti-platelet effects,
aspirin also has anti-inflammatory activity, which may
contribute to its clinical effectiveness in ACS (Fig. 1).
There have been four key randomized trials testing the
use of aspirin in unstable angina (Table 1) (13–16). These
early studies were performed in the 1970s and 1980s, before
the routine use of currently used therapies including hepa-
rin, clopidogrel and glycoprotein IIb/IIIa antagonists. They
were also performed before the widespread use of invasive
procedures such as PCI and coronary artery bypass graft
(CABG) surgery, which are now commonly performed in
patients with unstable angina and NSTEMI. Nevertheless,
these trials individually demonstrated benefits of aspirin
over both placebo and untreated control in reducing isch-
emic events, and they have led to the universal recommen-
dation of aspirin as standard therapy in ACS.
The first large study was the Veterans Affairs (VA) trial,
performed between 1974 and 1981, involving 1,338 patients
with unstable angina who were treated with 12 weeks of
aspirin versus control (13). This study demonstrated a 41%
reduction in death or MI (10.1% in the placebo group vs.
5.0% with acetylsalicylic acid, p  0.004) with 12 weeks of
treatment with aspirin at a dose of 325 mg daily (13).
Mortality was reduced in this trial from 3.3% to 1.6% (p 
0.054) with aspirin. In the Canadian Multicenter Trial
aspirin therapy was given much longer than in the VA trial,
for an average of 18 months after an episode of unstable
angina. This study of 555 patients was performed between
1979 and 1984 and demonstrated that aspirin (325 mg four
times daily) was superior to control, with a 30% reduction in
death or MI at two years (p  0.072 in the intention-to-
treat analysis) and a 43% reduction in death alone (p 
0.035) (14). In the Montreal Heart study (n  479), aspirin
(325 mg twice daily) given for a very short period (only 6
days) reduced death or MI by 63% (6.3% vs. 2.6%, p 
0.04) (15). In the Research on InStability Coronary artery
disease (RISC) study, aspirin in a lower dose of 80 mg daily
given for one year reduced death or MI by 49% in the 796
patients meeting the inclusion criteria (total of 945 patients
randomized) (21.4% vs. 11%, p  0.0001) (16).
In the Antithrombotic Trialists’ Collaboration overview
(17), among all patients who were at high risk for vascular
events, there was a 22% reduction in the composite of
vascular death, MI, or stroke (13.2% vs. 10.7%, p 
0.0001). Vascular death alone was reduced by 15% (p 
0.0001). Among the subset of patients with unstable angina,
there was a 46% reduction in vascular events (13.3% vs.
8.0%, p  0.0001) (Table 1).
Aspirin also reduces the frequency of ischemic complica-
tions when started before, and continued after, PCI. In an
early study of 376 patients undergoing (mostly elective)
angioplasty, patients were randomized to receive either
aspirin (990 mg) and dipyridamole (225 mg daily) or
placebo starting 24 h before angioplasty and continuing for
four to seven months after surgery (18). Although the
antiplatelet therapy had no effect on reducing the frequency
of restenosis, there was a large reduction in periprocedural
Q-wave MI when antiplatelet therapy was started before the
procedure (6.9% vs. 1.6%; p  0.011). In the only random-
ized trial of long-term aspirin therapy following angioplasty,
aspirin (325 mg daily) given for six months was associated
with a significant reduction in MI compared with placebo
(1.2% vs. 5.7%; p  0.03) (19).
Table 1. Randomized Trials of Acetylsalicylic Acid in Unstable Angina
Trial (Ref) Treatment Follow-Up Aspirin Control
Relative Risk
Reduction p Value
Veterans Affairs Study, 1983
(13)
ASA 325 mg daily vs. placebo 3 months 31/625 (5.0%) 65/641 (10.1%) 41% 0.004
Canadian Study, 1985 (14)* ASA 325 mg 4 times daily or
control
18 months (mean) 29/276 (10.5%) 41/279 (14.6%) 30%* 0.072
Montreal Heart Study, 1988
(15)
ASA 650 mg first dose then
325 mg twice daily for 6
days or placebo
6 days 6/243 (2.5%) 15/236 (6.4%) 63% 0.04
RISC, 1990 (16) ASA 75 mg for 3 months or
placebo
13 months 26/399 (6.5%) 68/397 (17%) 64% 0.0001
Antithrombotic Trialists’
Collaboration Meta-
analysis (17)†
Various regimens vs. placebo/
untreated control
various 8.0% 13.3% 46%  0.0001
*Intention to treat analysis is presented. Mortality alone was reduced by 43%, p  0.035. †End point reported is vascular death, MI, or stroke.
ASA  acetylsalicylic acid; RISC  Research on InStability in Coronary artery disease.
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The consistent benefit of aspirin in these early studies
provides clear proof that effective long-term antiplatelet
therapy can improve the prognosis in ACS and PCI.
Despite the proven benefits of aspirin, however, recurrent
events remain high (8). This underscores the need to
continue the search for new agents that can either replace or
be used in addition to aspirin for short- and long-term
management.
ADP receptor antagonists in atherothrombosis. The
ADP receptor antagonists, ticlopidine and clopidogrel, are
antiplatelet agents that inhibit the early step of platelet
activation (Fig. 1). They prevent platelet degranulation and
the release reaction, which elaborates prothrombotic and
inflammatory mediators from the platelet and also inhibits
the transformation of the GP IIb/IIIa receptor to the form
that binds fibrinogen and links platelets. These agents act
early in the sequence of events leading to the formation of
the platelet thrombus, effectively inhibiting platelet aggre-
gation. Ticlopidine and clopidogrel selectively and irrevers-
ibly prevent ADP from binding to the platelet ADP
receptor P2Y12 (20,21). (The active metabolite of clopi-
dogrel is a short-lived thiol derivative of the parent mole-
cule.)
Although both clopidogrel and ticlopidine have been
found to be useful clinically for patients with atherosclerosis,
ticlopidine is limited by its potential to cause severe neutro-
penia in about 1% of patients, necessitating close monitor-
ing of blood counts during the first few weeks or months of
treatment (22). Also, the full antiplatelet action of ticlopi-
dine is delayed for several days after therapy is initiated,
limiting its usefulness in acute situations. By contrast, the
full antiplatelet action of clopidogrel takes effect rapidly
after a 300 mg bolus, with almost maximal antiplatelet effect
observed after only 2 h (23).
In a randomized trial conducted 10 years ago that
compared ticlopidine with placebo in 662 patients with
unstable angina, there was a 46% reduction in the primary
end point of cardiovascular death or MI with ticlopidine
(p  0.009) (24). In the Clopidogrel versus Aspirin in
Patients at Risk of Ischemic Events (CAPRIE) trial, clopi-
dogrel was directly compared with aspirin in a broad range
of patients with atherosclerotic disease for the secondary
prevention of ischemic events (25). Patients in the clopi-
dogrel arm of the trial did not receive aspirin. Compared to
aspirin, and at a mean of 1.9 years follow-up, clopidogrel
was found to significantly reduce the primary outcome of
vascular death, MI, or ischemic stroke by 8.7% (95%
confidence interval [CI], 0.3% to 16.5%).
Combination therapy: aspirin and an ADP receptor
antagonist in patients after stenting. The ADP receptor
antagonists and aspirin act through complementary and
independent mechanisms, and their combination can in-
hibit both ADP-induced platelet aggregation and throm-
boxane A2 production (26–28). The superiority of this
combination compared with aspirin alone has been demon-
strated convincingly in several randomized trials in patients
after coronary artery stenting (29–34). A meta-analysis of
these trials found a clear benefit from aspirin plus ticlopidine
in reducing death and non-fatal MI compared with aspirin
alone (odds ratio [OR], 0.23; 95% CI, 0.11 to 0.49; p 
0.0001) or aspirin plus warfarin (OR, 0.51; 95% CI, 0.33 to
Table 2. Main Results From the CURE Trial
Placebo  Aspirin*
N  6303
Clopidogrel  Aspirin*
N  6259
Relative Risk
Reduction p Value
Cardiovascular death, MI,
or stroke
9.3% 11.4% 0.80 0.00009
Cardiovascular death 5.1% 5.5% 0.93
Stroke 1.2% 1.4% 0.86
Myocardial infarction 6.7% 5.2% 23%  0.001
ST elevation myocardial
infarction (Q-wave MI)
3.1% 1.9% 40%  0.001
Thrombolytic therapy 2.0% 1.1% 43%  0.001
Congestive heart failure 4.4% 3.7% 18% 0.03
Derived from: The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes
without ST segment elevation. N Engl J Med 2001; 345: 494–502.
*In addition to other standard therapies.
CURE  Clopidogrel in Unstable angina Recurrent Events; MI  myocardial infarction.
Figure 2. First co-primary outcome in Clopidogrel in Unstable angina to
prevent Recurrent ischaemic Events (CURE). Cardiovascular death, myo-
cardial infarction, or stroke from randomization up to one year of follow-up
(mean nine months). ASA acetylsalicylic acid. The CURE Investigators.
Effects of clopidogrel in addition to aspirin in patients with acute coronary
syndromes without ST segment elevation. N Engl J Med 2001;345:494–
502. Adapted with permission 2002. © 2002 Massachusetts Medical
Society. All rights reserved.
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0.78; p 0.002) (35). There have been several observational
studies and clinical trials comparing the effects of ticlopidine
with the effects of clopidogrel. A meta-analysis of the
studies (registries and clinical trials) suggests that the
aspirin-plus-clopidogrel combination is at least as efficacious
as the aspirin-plus-ticlopidine combination in patients re-
ceiving an intracoronary stent (36).
Aspirin and clopidogrel in ACS: the CURE trial. The
Clopidogrel in Unstable angina Recurrent Events (CURE)
trial was designed to test the hypothesis that the
clopidogrel-plus-aspirin combination is superior to aspirin
alone when initiated early and continued for the long term
in the prevention of cardiovascular death, MI, or stroke in
patients with NSTE ACS (unstable angina/NSTEMI)
(35). The CURE trial was a double-blind, placebo-
controlled, international, randomized trial of short- and
long-term therapy with clopidogrel versus placebo, in addi-
tion to aspirin and other contemporary therapies (including
low-molecular-weight and unfractionated heparin, beta-
blockers, ACE inhibitors, and lipid-lowering therapies) in
patients with NSTE ACS. Patients were eligible if they
presented within 24 h of chest pain onset and had objective
evidence of ischemia in the form of either elevated cardiac
enzymes (or troponin) or electrocardiogram changes com-
patible with myocardial ischemia (such as ST depression,
T-wave inversion, or transient ST elevation). Aspirin was
administered to all patients in doses of 75 to 325 mg
(median dose, 160 mg). After randomization, no restrictions
were placed on the use of other procedures (such as
percutaneous transluminal coronary angioplasty [PTCA] or
CABG surgery) or medications (including the GP IIb/IIIa
antagonists). Overall, 12,652 patients were recruited at 482
hospitals in 28 countries. Of these, 5,491 patients (44%)
underwent angiography, 2,072 (16.5%) had CABG surgery,
and 2,658 (21.2%) underwent PCI.
A highly significant 20% relative risk reduction (RR) was
found with clopidogrel versus placebo in the first co-primary
outcome of MI, stroke, or cardiovascular death (9.3% vs.
11.4%; relative RR, 0.80; 95% CI, 0.72 to 0.90; p 
0.00009) (Table 2, Fig. 2) (37). Consistent reductions were
observed in all components of the primary composite end
point, with a 7% reduction in cardiovascular death (5.1% vs.
5.5%; relative RR, 0.93) and a 14% reduction in stroke
(1.2% vs. 1.4%; RR, 0.86), but the clearest effect was a 23%
reduction in MI (5.2% vs. 6.7%; RR, 0.77). Of these, the
most pronounced reduction was in large MIs (with ST
elevation or Q-waves), which were reduced by a remarkable
40% (3.1% vs. 1.9%; RR, 0.60; 95% CI, 0.48 to 0.76).
Consistent with this decrease in large MIs was a reduction
in the use of thrombolytic therapy (2.0% vs. 1.1%; %RR,
0.57; p  0.001) and in new-onset congestive heart failure
with clopidogrel treatment (radiologically confirmed) (4.4%
vs. 3.7%; RR, 0.82; p 0.026). These data indicate that the
prevention of large MIs with clopidogrel therapy was
associated with improved ventricular function, emphasizing
the clinical importance of a reduction in these events
(Table 2).
Early benefit of clopidogrel. The effects of clopidogrel
became apparent very early after administration of the
300-mg loading dose, with divergence in the Kaplan-Meier
event curves occurring as early as 2 h after randomization.
Within 24 h of randomization, a highly significant 34%
reduction in cardiovascular death, MI, stroke, or severe
ischemia was evident (RR, 0.66; p  0.003). At 30 days,
clopidogrel reduced the first primary end point by 21% (p
0.001) (37). During the initial hospitalization, there were
reductions in a wide range of other ischemic events, includ-
ing refractory ischemia, which was defined as: 1) the
presence of recurrent chest pain while on maximal medical
therapy; 2) the presence of new electrocardiogram changes;
and 3) the performance of an intervention by midnight of
the next day (2.0% vs. 1.4%; RR, 0.68; p  0.007).
“Additional severe ischemia,” defined as recurrent chest pain
and new electrocardiogram changes (3.8% vs. 2.8%; RR,
0.74; p  0.003), and “recurrent angina,” which was any
other chest pain in hospital (22.9% vs. 20.9%; RR, 0.91; p
0.01), were also reduced. The very rapid emergence of
benefits with clopidogrel emphasizes the importance of
giving the loading dose immediately after the diagnosis is
made (preferably in the emergency room) to obtain the
greatest benefits in the largest number of patients.
Late benefit of clopidogrel. In the CURE trial, patients
were treated with study medication for a maximum of one
year after randomization (mean follow-up, nine months).
From day 31 up to one year, there was a highly significant
incremental reduction of 18% in the primary outcome with
clopidogrel (RR, 0.82; p  0.001) (37). This long-term
benefit was in addition to the rapid early benefit observed
within the first 30 days. Thus, therapy with clopidogrel
should continue for the long term—for at least nine months,
up to one year. Similar to aspirin, treatment with clopi-
dogrel longer than this period is reasonable, particularly in
those patients at increased risk of future events. Safety data
with clopidogrel is available for up to three years of
treatment in the CAPRIE study, where clopidogrel was
generally better tolerated than treatment with aspirin.
Benefit in addition to proven therapies. The benefit of
clopidogrel was observed in addition to standard therapies
already used in unstable angina or NSTEMI, such as aspirin
(99.1%), beta-blockers (77.5%), ACE inhibitors (48.9%),
lipid-lowering therapy (45.6%), and revascularization with
either CABG or PTCA (performed in 38%).
Benefit in all risk groups. When the CURE results were
stratified according to the TIMI risk score, significant
benefits were demonstrated across all levels of risk. Low-risk
(4.1% vs. 5.7%; RR, 0.71; RR, 1.6%; p  0.03),
intermediate-risk (9.8% vs. 11.4%; RR, 0.71; adjusted RR,
1.6%; p  0.02), and high-risk patients (15.9% vs. 20.7%;
RR, 0.73; adjusted RR, 4.8%; p  0.003) all benefited, but
the greatest absolute benefit was observed in the high-risk
patients (38).
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Patients with a history of CABG gained additional highly
significant advantage from clopidogrel treatment (RR, 0.55;
95% CI, 0.43 to 0.72). Patients undergoing CABG surgery
during the initial hospitalization in CURE had a consistent
19% reduction in the primary end point (95% CI, 0.59 to
1.12). Thus, clopidogrel is effective over and above current
therapies and across all risk levels, including those patients
undergoing CABG surgery after randomization. This em-
phasizes its value in a very wide spectrum of patients with
ACS, irrespective of other medical therapies or interven-
tions used.
PCI CURE. The PCI CURE study was a prospectively
planned substudy of CURE. Its goals were to investigate: 1)
whether patients randomized to clopidogrel derived benefit
from pretreatment with clopidogrel and aspirin therapy
before angioplasty compared with placebo and aspirin prior
to PCI; and 2) whether long-term therapy after PCI is
superior to placebo (35,39). Overall, 2,658 patients were
included, making PCI CURE one of the largest investiga-
tions of contemporary PCI in ACS. Percutaneous coronary
intervention was performed at the discretion of the site
investigator. After PCI, the vast majority of patients in both
treatment arms (80%) received open-label thienopyridine
for a median of 30 days, mainly because of stent placement.
Thus, the 30-day results reflect mainly the effects of
pretreatment with clopidogrel. The overall results of the
PCI CURE substudy from the time of randomization to the
end of follow-up (up to one year) revealed a highly signif-
icant 31% reduction in cardiovascular death or MI with
clopidogrel pretreatment plus long-term therapy after PCI
(12.6% vs. 8.8%; RR, 0.69; 95% CI, 0.54 to 0.87; p 
0.002) (Fig. 3). There was a 30% reduction in the primary
end point of cardiovascular death, MI, or urgent revascu-
larization from the time of PCI to 30 days (6.4% vs. 4.5%;
RR, 0.70; p  0.03), indicating that pretreatment with
clopidogrel was beneficial in preventing major events after
PCI. In the per-protocol analysis, when only patients
receiving an intracoronary stent were examined, there was a
44% relative RR in cardiovascular death, MI, or urgent
target revascularization with clopidogrel pretreatment, com-
pared with placebo (p  0.017) (40) (Fig. 4).
In the long term, there was a consistent benefit of
clopidogrel over placebo from 30 days after PCI to the
end of follow-up, during which there was a significant
reduction in the combined outcome of cardiovascular death,
MI, or rehospitalization (RR, 0.86; p  0.05). There was
also a concurrent reduction in the outcome of cardiovascular
death or MI (RR, 0.79; 95% CI, 0.53 to 1.20), consistent
with the highly significant overall RR in PCI CURE (Fig.
5) and the late (30 days) overall benefit in the CURE trial.
Furthermore, in patients who had PCI within 72 h of
Figure 3. Percutaneous Coronary Intervention-Clopidogrel in Unstable
angina to prevent Recurrent ischaemic Events (PCI CURE) trial: overall
long-term results from randomization up to one year: cardiovascular death
or myocardial infarction. A median time to PCI; B 30 days after PCI.
ASA  acetylsalicylic acid; PCI  percutaneous coronary intervention.
Reprinted with permission from Elsevier Science (The Lancet 2001;358:
527–33).
Figure 4. Effects of pretreatment with clopidogrel compared with placebo
in stented patients (excludes those receiving open-label thienopyridine
before percutaneous coronary intervention [PCI]). All patients received
open-label clopidogrel or ticlopidine for a median of 30 days after PCI.
Day 0 is the day of PCI. Reprinted with permission from Elsevier Science
(The Lancet 2002;359:169).
Figure 5. Cardiovascular (CV) death or MI in Percutaneous Coronary
Intervention-Clopidogrel in Unstable angina to prevent Recurrent isch-
aemic Events (PCI CURE): consistent benefits of clopidogrel at all
non-overlapping time points. MI myocardial infarction; RRR relative
risk ratio.
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admission (n  544), there was a consistent 38% RR in
cardiovascular death or MI (95% CI, 0.37 to 1.05; p 
0.076), compared with patients who delayed intervention
(RR, 29%; 95% CI, 0.54 to 0.92; p  0.01). The benefit of
clopidogrel was identical regardless of whether patients
underwent PCI during their initial hospitalization (12.0%
vs. 8.3%; RR, 0.68; 95% CI, 0.50 to 0.92; p  0.01) or after
discharge (13.8% vs. 9.8%; RR, 0.70; 95% CI, 0.48 to 1.02;
p 0.06). Thus, with both urgent and delayed intervention,
consistent benefits were associated with clopidogrel treat-
ment. Taken together, the data from CURE and PCI
CURE suggest that in patients with ACS, clopidogrel is
beneficial with long-term use, both in patients undergoing
PCI and in those treated medically.
Oral GP IIb/IIIa antagonists. There have been five large
randomized trials of oral GP IIb/IIIa antagonists in patients
with a wide range of atherosclerotic disease (41–45). Al-
though these agents once held great promise, there was
consistency among all of the randomized trials toward
increased mortality with a GP IIb/IIIa agent compared with
placebo. A meta-analysis of four large trials in patients with
ACS demonstrated a highly significant 37% increase in
mortality with the use of a GP IIb/IIIa antagonist (p 
0.001) (46) (Fig. 6). Thirty days after randomization, there
was a 40% higher incidence of MI associated with these
agents (p  0.002). Consistent with these results, the large
Global Use of Strategies to Open Occluded Arteries in
Acute Coronary Syndromes (GUSTO) IV trial of abcix-
imab in ACS demonstrated no benefit and perhaps a trend
toward increased mortality at 48 h, compared with 24-h
treatment with abciximab (RR, 2.3; p  0.048 after 24-h
abciximab treatment vs. placebo; RR, 2.9; p  0.007 after
48-h abciximab treatment vs. placebo) (47). In this trial,
there was no benefit associated with abciximab in higher-
risk patients (e.g., with elevated troponin I or T or those
with ST depression at baseline). These results contrast with
the proven benefits of short durations of treatment with
abciximab and other IV GP IIb/IIIa agents in the setting of
PCI (whether or not patients were diagnosed with ACS)
(48,49).
The reasons for the increase in mortality with the
prolonged use of certain GP IIb/IIIa antagonists in ACS
remain speculative. The basic pharmacology and pharma-
codynamics of these compounds may be at the root of the
problem. However, given the similarities across a wide range
of compounds within this class and the heterogeneous
clinical conditions in which they have been tested, such
considerations are probably of minor relevance. Another
factor may be their basic mechanism of action, which occurs
at a relatively late step in the formation of a platelet-rich
thrombus. For example, GP IIb/IIIa inhibitors do not affect
platelet activation and degranulation, unlike ADP receptor
antagonists, which are active at these much earlier stages of
the atherothrombotic process, where the environmental
milieu required for the initiation and propagation of throm-
bosis is created. This becomes particularly important with
long-term therapies. Interestingly, the oral GP IIb/IIIa
inhibitor trials also demonstrated a highly significant 78%
excess in the incidence of major bleeding. Some have
argued, therefore, that they did exert a clinically apparent
antiplatelet effect, raising the possibility that the reported
increase in mortality may be due to a direct toxic effect of
these agents (46).
Bleeding in trials of antithrombotic therapies in ACS.
There is some variability in the definitions of major bleeding
used in the various studies of antiplatelet therapy in unstable
angina/NSTEMI. For example, TIMI “major bleeding”
(from the Thrombolysis In Myocardial Infarction trial),
GUSTO “severe or life-threatening bleeding,” and CURE
“major or life-threatening bleeding” are three commonly
used terms for major bleeding. The original criteria for a
TIMI “major bleed” are bleeding leading to a hemoglobin
drop of 5 g/dl or an intracranial hemorrhage (50). This
definition was reported in several large trials of antithrom-
botic therapy in unstable angina or NSTEMI (51,52). In
some trials, a modified TIMI definition has been used, in
which each unit of blood transfused is counted as a 1 g/dl
drop in hemoglobin. The CURE definition of “life-
threatening bleeding” includes not only the two criteria used
in the TIMI “major bleeding” definition but also, expanding
on this definition, the following criteria: 4 U of red
blood-cell transfusion, surgery required to stop bleeding, or
any fatal bleed. This CURE “life-threatening bleeding”
definition is only a subset of “major bleeding” in CURE and
also encompasses “non-life-threatening bleeding,” defined
as a blood transfusion of at least 2 U or bleeding leading to
significant disability. The CURE “major bleeding” defini-
tion is therefore considerably broader than that used in
other large randomized trials of ACS, an important consid-
Figure 6. Excess mortality with oral glycoprotein IIb/IIIa antagonists. All
trials demonstrate a consistent increase in total mortality. p  0.5888
Breslow-Day heterogeneity. CI  confidence interval; EXCITE  Eval-
uation of oral Xemilofiban In controlling Thrombotic Events trial;
OPUSOptimal angioplasty and primary stenting trial; SYMPHONY
Sibrafiban vs. aspirin to Yield Maximum Protection from ischemic Heart
events pOst acute coroNary sYndromes. Chew DP, Bhatt DL, Sapp S,
Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa
antagonists: a meta-analysis of phase III multicenter randomized trials.
Circulation 2001;103:201–6. Reproduced with permissions from Lippin-
cott, Williams and Wilkins.
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eration when comparing its results with those of various
other trials.
Table 3 shows the data for bleeding incidence in CURE
using the CURE life-threatening definition as well as the
TIMI and GUSTO definitions, demonstrating how, de-
pending on the definition used, the relative risk of bleeding
can vary. Because of its large sample size, CURE had more
power to assess bleeding incidence than the other ACS
trials. Also in this trial, it is important to note that with
clopidogrel there was no increase in fatal bleeding, bleeding
that required surgical intervention (including post-CABG
re-intervention), or intracranial hemorrhage.
Table 4 summarizes the efficacy and bleeding data for
contemporary antithrombotic therapies, with distinctions
between comparisons of short-term treatments with both
short- and long-term therapies (53–55). In the intravenous
GP IIb/IIIa antagonist trials, an increase of 62% in major
bleeding at 30 days is shown (2.4% vs. 1.4%; RR, 1.62; 95%
CI, 1.36 to 1.94; p  0.0001) (53). For the trials of oral GP
IIb/IIIa inhibitors, there is a relative 74% increase in major
bleeding compared with placebo (2.4% vs. 4.1%; OR, 1.74;
p  0.001) (46). The aspirin trials revealed an increase in
major bleeding of about 60% (1.13 vs. 0.71; RR, 1.6) (17).
In the CURE trial, there was a 38% increase in major
bleeding (combined non-life-threatening plus life-
threatening bleeding) in the clopidogrel group compared
with the placebo group (3.7% vs. 2.7%; p  0.001), with no
significant increase in life-threatening bleeding alone (p 
0.13) (37).
In PCI CURE, no significant increase was found in
major or life-threatening bleeding with clopidogrel treat-
ment (38). There was also no increase in bleeding with
concurrent use of GP IIb/IIIa inhibitors and clopidogrel
compared with placebo.
Overall, there was no significant increase in bleeding in
the patients (numbering more than 2,000) who underwent
CABG surgery after randomization in the CURE trial. The
CURE trial is one of the largest randomized investigations
of antiplatelet therapy in ACS patients undergoing CABG
surgery. In this trial, patients requiring CABG surgery were
given clopidogrel in the same manner as aspirin. For
example, if aspirin was discontinued for several days before
CABG, then it was also recommended that the study drug
be discontinued for this period. Most patients undergoing
CABG in CURE had the study drug stopped for a short
period of time before surgery. If surgery was urgent,
Table 3. Bleeding in CURE According to TIMI Major,
GUSTO Severe, and CURE Life-Threatening Definitions (37)
Placebo
N  6,303
Clopidogrel
N  6,259
Relative
Risk
p
Value
CURE Life-threatening 112 (1.8%) 135 (2.2%) 1.21 0.13
GUSTO Severe 70 (1.1%) 78 (1.2%) 1.12 0.48
TIMI Major 73 (1.15%) 68 (1.1%) 0.94 0.70
CURE  Clopidogrel in Unstable angina Recurrent Events; GUSTO  Global Use
of STrategies to Open occluded arteries in acute coronary syndromes; TIMI 
Thrombolysis In Myocardial Infarction.
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however, CABG proceeded while the patient was still
receiving the study drug, as would be the case with aspirin.
In those patients in whom the study drug was withheld for
five or more days prior to CABG, no increase in bleeding
was noted (37). When the study drug was administered
within five days prior to CABG (including up to the time of
surgery), there was a trend toward an increase in major
bleeding (RR, 1.56; p  0.06), suggesting that it may be
better to withhold clopidogrel for a few days prior to
CABG, if possible (37). Patients undergoing CABG sur-
gery after randomization had consistent benefits from clo-
pidogrel, and those patients at highest risk (in terms of
TIMI risk score) had the greatest absolute benefit. This
suggests that all patients who receive clopidogrel early will
benefit irrespective of whether their medical management
involves PCI or CABG surgery.
Overall risk-benefit ratio. The relative benefits of various
antiplatelet therapies versus placebo are shown in Table 4.
Apart from aspirin, clopidogrel is associated with the largest
reduction in relative risk for death or MI in the setting of
ACS, compared with other therapies. In CURE, when the
primary composite of cardiovascular death, MI, or strokes
(all irreversible events) and life-threatening bleeds (mostly
reversible) are combined into an efficacy-safety end point,
there remains a highly significant benefit of clopidogrel over
placebo (RR 0.84; 95% CI, 0.76 to 0.93; p  0.001). If one
expands this outcome to include refractory ischemia requir-
ing intervention or major bleeding, the RR is 0.87 (95% CI,
0.79 to 0.96; p  0.005). Similar risk-benefit values for
other antithrombotic agents in ACS have not been re-
ported.
Conclusions. Oral anti-platelet therapies have had a sig-
nificant impact in preventing major cardiovascular events in
patients with NSTE ACS. Aspirin, when administered
early and continued for the long term, reduced major
ischemic events, including death, MI, and stroke. Develop-
ment of the oral GP IIb/IIIa antagonists has been disap-
pointing, with either no benefit or a trend toward increased
mortality observed in the large, randomized trials testing
these agents. By contrast, when the ADP receptor antago-
nist clopidogrel is added to aspirin, there are incremental
reductions in major events, compared with aspirin treatment
alone. These benefits emerge very rapidly (as early as 2 h)
after administration of a 300-mg loading dose, indicating
the importance of starting clopidogrel as early as possible.
When aspirin and clopidogrel are continued over the long-
term (i.e., beyond 30 days) there is a highly significant,
incremental 20% reduction in major events with treatment
up to one year. These benefits are observed in patients
undergoing PCI and CABG surgery after presentation. For
patients undergoing PCI who are pretreated with clopi-
dogrel and aspirin and who receive long-term therapy (up to
one year) after intervention, a 31% risk reduction in cardio-
vascular death or MI has been found. This benefit is
independent of the timing of PCI, with consistent reduc-
tions observed among patients undergoing very early PCI
(within 72 h) as well as among those undergoing PCI at a
later date.
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